医薬品リファレンス
Eltrombopag
Eltrombopag is a medicine in the class miscellaneous. It is used for aplastic anemia.
- 薬効分類: Miscellaneous
- 効能・効果: aplastic anemia
最終更新日
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Miscellaneous
- ATCコード
- B02BX05
- 一般的な剤形
- 錠剤, 経口懸濁液
- 一般的な規格
- 50 mg, 25 mg
- 既知の相互作用
- 124 (中等度: 66 · 軽度: 58)
- 商品名
- 14
- 国・市場
- 5
何に使われるか
作用のしくみ
Small-molecule thrombopoietin (TPO)-receptor agonist that interacts with human TPO receptor transmembrane domain of human TPO-receptor & initiates signaling cascades that induce proliferation & differentiation of megakaryocytes from bone marrow progenitor cells
成人の通常用量（添付文書の要約）
Chronic Immune Thrombocytopenia (ITP): Initial: 50 mg PO qDay, Adjust dose to achieve and maintain platelet count (Plt) >50 x 10^9/L to reduce risk of bleeding; not to exceed 75 mg/day.
妊娠と授乳
- 妊娠
- Unknown Case reports are too few to assess risk; in rats, maternally toxic doses caused embryo death and lower fetal weight. EU label: not recommended in pregnancy or in women not using contraception. Use effective contraception during and for 7 days after treatment.
- 授乳
- Unsafe No human milk data; it reached rat pups through milk. US label: breastfeeding not recommended. It clears about 8 days after the last dose. LactMed: one infant had prolonged high platelets; if used, monitor the infant's blood counts.
報告されている副作用
- Headache
- Fatigue
- Upper respiratory tract infection
- Nasopharyngitis
- Nausea
- Anemia
注意が必要な方
- May develop or worsen cataracts; screen before administering and during treatment
- Thrombotic/thromboembolic complications reported; have included both venous and arterial events and were observed at low and at normal platelet counts.
- Portal vein thrombosis reported in patients with chronic liver disease receiving therapy
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (124)
- Alpelisib + Eltrombopag Moderate
- Aluminum hydroxide + Eltrombopag Moderate
- Amobarbital + Eltrombopag Moderate
- Artesunate + Eltrombopag Moderate
- Atazanavir + Eltrombopag Moderate
- Atorvastatin + Eltrombopag Moderate
- Berotralstat + Eltrombopag Moderate
- Butabarbital + Eltrombopag Moderate
- Butalbital + Eltrombopag Moderate
- Calcium + Eltrombopag Moderate
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Eltrombopagの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Paediatric dosing
- Patient counselling points
- Food interactions
WebでPro+を14日間無料でお試し。カード登録不要。
よくある質問
What is Eltrombopag used for?
Eltrombopag is a medicine in the class miscellaneous. It is used for Aplastic anemia, Thrombocytopenia.
What side effects have been reported with Eltrombopag?
Headache, Fatigue, Upper respiratory tract infection, Nasopharyngitis, Nausea, Anemia.
Can Eltrombopag be taken in pregnancy or while breastfeeding?
Pregnancy: Unknown. Case reports are too few to assess risk; in rats, maternally toxic doses caused embryo death and lower fetal weight. EU label: not recommended in pregnancy or in women not using contraception. Use effective contraception during and for 7 days after treatment. Breastfeeding: Unsafe. No human milk data; it reached rat pups through milk. US label: breastfeeding not recommended. It clears about 8 days after the last dose. LactMed: one infant had prolonged high platelets; if used, monitor the infant's blood counts.
What does Eltrombopag interact with?
MediHelp lists 124 known interactions for Eltrombopag. Moderate: 66 · Minor: 58. The most serious include Alpelisib, Aluminum hydroxide, Amobarbital.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
